Core Insights - Caris Life Sciences Inc. reported better-than-expected fourth-quarter earnings, with earnings of 28 cents compared to a consensus loss of 3 cents, and sales increased by 125% year over year to $292.89 million, surpassing the consensus of $208.63 million [1] Group 1: Financial Performance - The company achieved fourth-quarter earnings of 28 cents, significantly exceeding the expected loss of 3 cents [1] - Sales for the quarter rose 125% year over year to $292.89 million, beating the consensus estimate of $208.63 million [1] Group 2: Future Growth Prospects - The demand for Caris Life Sciences' platform is accelerating, contributing to strong growth in volume and revenue, with plans to launch the Caris Detect solution in the first half of 2026, which is seen as a significant growth opportunity [2] - The company reported advancements in its multi-cancer early detection test, Caris Detect, which utilizes Whole Genome Sequencing to improve early cancer detection capabilities [3] Group 3: Market Reaction and Analyst Ratings - Following the earnings announcement, Caris Life Sciences shares increased by 14.1% to $21.95 in pre-market trading [3] - Analysts have adjusted their price targets for Caris Life Sciences, with BTIG maintaining a Buy rating and lowering the target from $45 to $38, Baird maintaining an Outperform rating and raising the target from $26 to $28, and Evercore ISI Group maintaining an Outperform rating and lowering the target from $38 to $34 [4]

Caris Life Sciences Inc. (NASDAQ:CAI) shares are up during Friday’s premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company’s Achieve 1 study.Sales More Than DoubledCaris Life Sciences on Thursday reported fourth-quarter earnings of 28 cents compared to the consensus loss of 3 cents.Sales for the quarter jumped 125% year over year to $292.89 million, beating the consensus of $208.63 million.The increase was driven primarily by a 199% growth ...

Core Insights - Caris Life Sciences announced an interim readout of the Achieve 1 study, demonstrating the effectiveness of its multi-cancer early detection test, Caris Detect, which utilizes Whole Genome Sequencing and advanced AI technology [1] Study Results - The Achieve 1 study evaluated Caris Detect's ability to detect multiple cancer types at early stages using blood samples from a population with a higher likelihood of cancer [1] - Key performance metrics include: - Sensitivity for Stage IV: 99.1% (n=109) - Sensitivity for Stage III: 77.1% (n=105) - Sensitivity for Stage II: 70.1% (n=137) - Sensitivity for Stage I: 56.8% (n=266) - Overall sensitivity for Stage I and II cancers: 61.3% [1] - Specificity was reported at 99.1% in the asymptomatic screening population (n=121) and 95.3% in the undiagnosed population (n=1,505) [1] Population Insights - The study included 1,505 undiagnosed subjects, with approximately 7% subsequently diagnosed with cancer within one year, indicating a high-risk enrollment [1] - Among the 121 subjects with follow-up data, none exhibited symptoms or significant risk factors for cancer and were not diagnosed within one year [1] Technological Approach - Caris Detect's methodology is based on a broader biological perspective, incorporating various genomic alterations beyond just epigenomics, which enhances its performance metrics compared to other detection methods [1] - The next version of Caris Detect is in development, aiming to further improve its performance by integrating Whole Transcriptome Sequencing [1] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced AI and machine learning to analyze complex molecular data for early detection and diagnosis of diseases [1] - The company has processed over one million cases and generated more than 50 billion molecular markers, establishing a robust molecular profiling foundation [1]

Financial Data and Key Metrics Changes - Caris Life Sciences reported total revenues of $293 million for Q4 2025, representing a 125% year-over-year increase, driven primarily by clinical profiling services [7][8] - Gross margins improved to 75% on a GAAP basis, up from 54% in Q4 2024, and a sequential increase from 68% in Q3 2025 [8] - The company generated positive GAAP net income of $82 million and adjusted EBITDA of $106 million for Q4 2025, marking the third consecutive quarter of positive adjusted EBITDA and free cash flow [9] Business Line Data and Key Metrics Changes - Molecular profiling services revenues increased to $282 million in Q4 2025, a 199% year-over-year increase [7] - Pharma R&D services revenues were $10.8 million in Q4 2025, with ongoing progress in CDX and data discovery [8] - For the full year, molecular profiling revenues increased 120% to $766.7 million, driven by a 22% year-over-year growth in clinical case volumes [12][13] Market Data and Key Metrics Changes - The company completed nearly 200,000 individual cases in 2025, contributing to a data set that now exceeds 1 million profiled cases [6][10] - The average sales price (ASP) for tissue increased by 83% to over $4,000, while blood ASP increased by 69% to just under $2,800 [13][14] Company Strategy and Development Direction - Caris aims to make precision medicine a reality, focusing on developing a revolutionary cancer early detection test, Caris Detect, expected to launch in Q2 2026 [10][11] - The company plans to invest in its commercial channel to broaden reach and deepen relationships, with a new chief commercial officer leading these initiatives [11][12] - The strategy includes maintaining financial discipline while investing in technology and product development to enhance offerings [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth opportunities in the market, emphasizing the need for advanced technology in cancer treatment [81] - The company expects total revenue for existing solutions in 2026 to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23%-26% compared to 2025 [41] - Management highlighted the importance of maintaining positive adjusted EBITDA and free cash flow while funding investments in growth [44] Other Important Information - The company ended 2025 with over $800 million in cash, reflecting a strong balance sheet [9][34] - Caris is preparing for a significant increase in capital expenditures, expected to reach approximately $60 million in 2026, primarily for the early detection launch [44][85] Q&A Session Summary Question: Volume outlook and revenue pacing for Q1 - Management indicated a total volume growth of 20%, with lower teens for tissue and high 50s to lower 60s for blood, and Q1 revenue growth is expected to be in the 70%-74% range [48] Question: Sales force expansion and its impact - The sales force is expected to increase from about 250 to approximately 300 people, with anticipated benefits in H1 of 2026, though not incorporated into the 20% growth guidance [50][51] Question: Specificity data and population definitions - Management clarified that the higher-risk population showed a 7% undiagnosed cancer rate, which affects specificity estimates, and emphasized the importance of characterizing test performance across different populations [54][56] Question: ASP assumptions for fiscal 2026 - The guidance for blood ASP is set at $2,400-$2,500, with tissue ASP expected to reach approximately $4,200 for the full year [72][76] Question: Rationale for increased OpEx spend - The increase in OpEx is primarily for sales and marketing and R&D, with expectations for new sales representatives to become productive within about six months [78][80]

Financial Data and Key Metrics Changes - Caris Life Sciences reported total revenues of $293 million for Q4 2025, a 125% increase year-over-year, driven primarily by clinical profiling services [7][8] - Gross margins improved to 75% on a GAAP basis, up from 54% in Q4 2024, and a sequential increase from 68% in Q3 2025 [8][9] - The company generated positive GAAP net income of $82 million and adjusted EBITDA of $106 million for the quarter, marking the third consecutive quarter of positive adjusted EBITDA and free cash flow [9][10] - Cash on hand grew to slightly above $800 million, an increase of $43 million in the quarter [9] Business Line Data and Key Metrics Changes - Molecular profiling services revenues increased to $282 million in Q4 2025, representing a 199% year-over-year increase [7][8] - Pharma R&D services revenues were $10.8 million in Q4 2025, with expectations to build on momentum from the Genentech discovery deal [8][31] - For the full year, molecular profiling revenues increased 120% to $766.7 million, driven by a 22% year-over-year growth in clinical case volumes [12][13] Market Data and Key Metrics Changes - The company completed just under 200,000 individual cases in 2025, contributing to a molecular dataset that now exceeds 1 million profiled cases [6][10] - The average sales price (ASP) for tissue increased by 83% to over $4,000, while blood ASP increased by 69% to just under $2,800 [13][34] Company Strategy and Development Direction - Caris aims to make precision medicine a reality, focusing on developing a revolutionary cancer early detection test, Caris Detect, expected to launch in Q2 2026 [10][11] - The company plans to invest in its commercial channel to broaden reach and deepen relationships, with a new chief commercial officer leading these initiatives [11][15] - The strategy includes maintaining financial discipline while investing in technology and product development to enhance offerings [12][41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth opportunities in the market, emphasizing the need for advanced technology in cancer treatment [76] - The company expects total revenue for existing solutions in 2026 to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23%-26% compared to 2025 [38] - Management highlighted the importance of maintaining positive adjusted EBITDA and free cash flow while funding investments in growth [41] Other Important Information - The Achieve 1 interim results for the Caris Detect test showed strong sensitivity and specificity, indicating promising performance for early cancer detection [20][23] - The company plans to allocate approximately $60 million in capital expenditures for 2026, primarily for the early detection launch and capacity expansion [41][80] Q&A Session Summary Question: Volume outlook and revenue pacing for Q1 - Management indicated a total volume growth of 20%, with lower teens for tissue and high 50s to lower 60s for blood, and projected Q1 revenue growth in the range of 70%-74% [44] Question: Sales force expansion and its impact - The sales force is expected to increase from about 250 to approximately 300 people, with anticipated benefits in the second half of the year [46][47] Question: Specificity data for cancer detection - Management clarified the difference between asymptomatic screening and undiagnosed populations, emphasizing the importance of clinical context in interpreting test performance [50][51] Question: Pharma R&D spending environment - Management expressed confidence in benefiting from increased pharma spending on AI, supported by a robust molecular dataset [52] Question: ASP assumptions for fiscal 2026 - Management guided blood ASP in the range of $2,400-$2,500 and tissue ASP expected to reach approximately $4,200 for the full year [66][70] Question: Rationale for increased OpEx spend - The increase in operating expenses is focused on sales and marketing, as well as R&D, to support growth initiatives and product development [72][73]

Financial Data and Key Metrics Changes - Caris Life Sciences reported total revenues of $293 million for Q4 2025, a 125% increase year-over-year, driven primarily by clinical profiling services [5][6] - Gross margins improved to 75% on a GAAP basis, up from 54% in Q4 2024 and 68% in Q3 2025 [7] - The company generated positive GAAP net income of $82 million and adjusted EBITDA of $106 million for the quarter, marking the third consecutive quarter of positive adjusted EBITDA and free cash flow [8][9] - Cash on hand increased to slightly above $800 million, reflecting a $43 million increase in the quarter [8] Business Line Data and Key Metrics Changes - Molecular profiling services revenues reached $282 million in Q4 2025, representing a 199% year-over-year increase [6] - Pharma R&D services revenues were $10.8 million in Q4, with ongoing progress in collaborations such as the Genentech discovery deal [6] - For the full year, molecular profiling revenues increased 120% to $766.7 million, driven by a 22% year-over-year growth in clinical case volumes [11] Market Data and Key Metrics Changes - The company completed nearly 200,000 individual cases in 2025, contributing to a data set that now exceeds 1 million profiled cases [5][9] - The average sales price (ASP) for tissue increased by 83% to over $4,000, while blood ASP increased by 69% to just under $2,800 [11] Company Strategy and Development Direction - Caris aims to make precision medicine a reality, focusing on technological innovation at the intersection of molecular science and AI [5] - The company plans to invest significantly in early detection and therapy selection channels in 2026, including the launch of a revolutionary cancer early detection test, Caris Detect [9][10] - The strategy includes maintaining financial discipline while expanding commercial reach and deepening relationships with oncologists [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth opportunities in the market, emphasizing the need for advanced technology in cancer treatment [76] - The company expects total revenue for existing solutions in 2026 to be in the range of $1.0 billion to $1.02 billion, representing growth of approximately 23%-26% compared to 2025 [35] - Adjusted EBITDA and free cash flow are expected to remain positive in 2026 while funding investments in commercial expansion and R&D [38] Other Important Information - The Achieve 1 interim results for the Caris Detect test showed strong sensitivity and specificity, with an AUC of 0.90 across a large dataset [20][21] - The company plans to allocate approximately $60 million in CapEx for 2026, primarily for testing equipment and capacity expansion related to the early detection launch [80] Q&A Session Summary Question: Volume outlook and revenue pacing - Management guided a total volume growth of 20%, with lower teens for tissue and high 50s to lower 60s for blood [41] Question: Sales force expansion and impact - The sales force is expected to increase from about 250 to approximately 300 people, with anticipated benefits in the second half of the year [44][45] Question: Specificity data and population definitions - The higher-risk population showed a 7% undiagnosed cancer rate, which affects specificity estimates [48][49] Question: Pharma R&D spending environment - The company expects to benefit from increased pharma spending on AI, supported by its extensive molecular data set [50][51] Question: ASP assumptions for 2026 - Guidance for blood ASP is set at $2,400-$2,500, while tissue ASP is expected to reach approximately $4,200 for the full year [66][70]

Q4 2025 Earnings Call February 26, 2026 Important Information and Disclaimer Where Molecular Science Meets Artificial Intelligence Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding our business, solutions, plans, object ...

Core Insights - Caris Life Sciences reported a significant revenue growth of 97% for the full year 2025, driven by strong performance in molecular profiling services [1] - The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, indicating a growth of approximately 23% to 26% compared to 2025 [1] Financial Highlights - Fourth Quarter 2025 total revenue was $292.9 million, a 125% increase from $129.9 million in Q4 2024, primarily due to a 199% growth in molecular profiling services revenue [1][3] - Full Year 2025 total revenue reached $812.0 million, up from $412.3 million in 2024, with molecular profiling services revenue growing by 120% to $766.7 million [1][3] - Gross margin improved to 75% in Q4 2025 from 54% in Q4 2024, and for the full year, it was 66%, up from 43% in 2024 [1][3] Operating Performance - The company completed approximately 52,700 clinical therapy selection cases in Q4 2025, a 20% increase year-over-year, and around 199,300 cases for the full year, a 22% increase [1] - Positive net cash provided by operating activities was $44.8 million in Q4 2025, compared to a net cash used of $38.9 million in Q4 2024, marking a 215% improvement [1][3] Future Outlook - Caris anticipates clinical therapy selection volume to grow approximately 20% in 2026 compared to 2025 [1] - The company announced a collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need [1]

Company Overview - Caris Life Sciences has a comprehensive oncology database with over 1,016,000 molecular profiles[5] - The company has a global presence with over 1,800 employees[7] - Caris has established a Precision Oncology Alliance (POA) with 99 leading cancer centers[5] Data and Technology - The company has profiled over 1 million cases in its genomic dataset[9] - Caris possesses over 627,000 whole exomes and 678,000 whole transcriptomes[9, 11] - The company has access to over 740,000 profiles with matched molecular data and clinical outcomes[11] Market Trends and Reach - Cancer centers are standardizing molecular profiling towards technology and service leaders[13] - Caris has a field-based team of approximately 250 and 50 MSLs serving over 6,000 oncologists in the US[18] - The company has integrated ordering locations in over 3,350 EHRs[18] Financial Performance - Caris achieved $281 million in revenue in Q4 2025, representing a 116% year-over-year growth[35, 67] - The company's total revenue increased to $800 million in FY 2025, a 94% increase year-over-year[69] - Molecular profiling services revenue increased to $755 million, a 116% increase year-over-year[69]

Core Insights - Caris Life Sciences has announced a partnership with Everlywell to launch Caris Detect, a Multi-Cancer Early Detection (MCED) blood-based screening assay utilizing whole genome sequencing (WGS) technology [1][2][3] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI technologies [4][5] - Everlywell is a digital health company that combines AI technology with human insight to provide personalized health answers, having delivered nearly 1 billion health insights and transformed care for 60 million people [6] Partnership Details - The partnership aims to enhance access to Caris Detect testing, which is designed to identify multiple cancer types at early stages, ultimately supporting better patient outcomes [3] - Caris expects to launch the Caris Detect assay in the first half of 2026, leveraging Everlywell's consumer-focused platform and established infrastructure [3]